Comparison of ICD shock rates in Japanese and non‐Japanese patients in the PainFree SST study

Kurita, Takashi; Ando, Koji; Ueda, Marehiko; Shizuta, Satoshi; Okamura, Hideo; Matsumoto, Naoki; Gerritse, Bart; Fagan, Dedra H.; Schloss, Edward J.; Meijer, Albert; Auricchio, Angelo; Sterns, Laurence D.; Okumura, Ken

doi:10.1111/pace.13427

Cited by 2 publications

(2 citation statements)

References 23 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the 85 patients, 45 patients experienced multiple episodes and the other 40 patients had a single episode of ATP therapy for fast VT. Average number of the fast VT episodes in each patient was 2.4 ± 2.9 1‐22 times. ATP successfully terminated 151 of the 202 fast VT episodes (74.8%) in total.…”

Section: Resultsmentioning

confidence: 99%

“…ATP used to be programmed for VT with relatively slow heart rate (HR), while immediate cardioversion had been chosen for VT with fast HR. However, as compared to cardioversion, ATP has various advantages (including better quality of life, less frequent psychological problems, longer battery longevity, and avoiding shock‐induced cardiac dysfunction), and these have been consistently confirmed in various patients’ backgrounds in many studies 3‐5 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Patient‐by‐patient basis anti‐tachycardia pacing for fast ventricular tachycardia with structural heart diseases

Chinushi¹,

Furushima²,

Saitoh³

et al. 2020

Pacing Clinical Electrophis

Self Cite

View full text Add to dashboard Cite

Background Anti‐tachycardia pacing (ATP) delivered from an implantable device is an important tool to terminate ventricular tachycardia (VT). But its real‐world efficacy for fast VT has not been fully studied. Methods Using the database of Nippon‐storm study, effect of patient‐by‐patient basis ATP programming for fast VT (≥188 bpm) was assessed for the patients with structural heart diseases. Fast VTs were divided into three groups depending on heart rate (HR); Group A was 188–209 bpm, and Group‐B and Group‐C were 210‐239 bpm and ≥240 bpm, respectively. Results During a median follow‐up of 28 months, 202 fast VT episodes (209 ± 19 bpm) were demonstrated in the 85 patients. ATP terminated 151 of the 202 episodes (74.8%) in total. The success rate of the ATP was not different among the three groups: 73.3% in Group A, 80.6% in Group B, and 66.7% in Group C. ATP success rate of >50% and >70% was 77.6% and 64.7% of the patients, respectively. Left ventricular ejection fraction (LVEF) was significantly higher in the patients with rather than without successful ATP therapy, and receiver operating characteristic (ROC) analysis revealed that LVEF of 23% was the optimal cut‐off value. ATP was less effective in patients taking amiodarone, but etiology of the structural heart diseases, indication of the device implantation, and all Electrocardiogram (ECG) parameters were not useful predictors for successful ATP therapy. Conclusions ATP highly terminated fast VT with wide HR ranges in patients with structural heart diseases, and should be considered as the first‐line therapy for fast VT except for patients with very low LVEF.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%